ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Nicolas Larmonier et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
80 papers cite itlatest 60 shown
this papercites it